These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 26483003)

  • 1. One-year outcomes of the U.S. and Japanese regulatory trial of the Misago stent for treatment of superficial femoral artery disease (OSPREY study).
    Ohki T; Angle JF; Yokoi H; Jaff MR; Popma J; Piegari G; Kanaoka Y;
    J Vasc Surg; 2016 Feb; 63(2):370-6.e1. PubMed ID: 26483003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Multicenter Comparison of S.M.A.R.T. CONTROL and MISAGO Stents in Treatment of Femoropopliteal Lesions.
    Suzuki K; Takahara M; Shintani Y; Tanaka A; Soga Y; Yamaoka T; Tosaka A; Sasaki S; Kawasaki D; Tsuchiya T; Kozuki A; Iida O
    J Vasc Interv Radiol; 2016 Nov; 27(11):1642-1649. PubMed ID: 27567999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-Year Efficacy and Safety of the Misago Peripheral Stent for Superficial Femoral Artery Disease: Final Results from the OSPREY Trial.
    Angle JF; Gasparetto A; Yokoi H; Jaff MR; Popma JJ; Piegari GN; Iyengar SS; Ohki T
    J Vasc Interv Radiol; 2020 Jun; 31(6):978-985. PubMed ID: 32414572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stent fractures after superficial femoral artery stenting: risk factors and impact on patency.
    Lin Y; Tang X; Fu W; Kovach R; George JC; Guo D
    J Endovasc Ther; 2015 Jun; 22(3):319-26. PubMed ID: 25862365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.
    Ohki T; Yokoi H; Kichikawa K; Kimura T; Snyder SA; Ragheb AO; O'Leary EE; Jaff MR; Ansel GM; Dake MD
    J Endovasc Ther; 2014 Oct; 21(5):644-53. PubMed ID: 25290792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MISAGO 2: one-year outcomes after implantation of the Misago self-expanding nitinol stent in the superficial femoral and popliteal arteries of 744 patients.
    Schulte KL; Kralj I; Gissler HM; Bagnaschino LA; Buschmann I; Pernès JM; Haage P; Goverde P; Beregi JP; Válka M; Boudny J; Geibel T; Velkoborsky M; Zähringer M; Paetzel C; Fanelli F; Müller-Hülsbeck S; Zeller T; Langhoff R
    J Endovasc Ther; 2012 Dec; 19(6):774-84. PubMed ID: 23210876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of the EPIC™ nitinol vascular stent system for the treatment of lesions located in the superficial femoral artery: prospective and multicentric trial.
    Nasser F; Kambara A; Abath C; Cavalcanti D; Barros I; Pires N; Rivera M; Neser A; Ingrund J; Burihan M; Silveira P; Galego G; Bortoluzzi C; Franklin R; Bosiers M; Deloose K; Razuk A; Caffaro R; Karakhanian WK; Park J; Lopes C; Pinto D; Bez L; Lopes R; Mourão A; Kleinsorge G
    J Cardiovasc Surg (Torino); 2017 Jun; 58(3):409-415. PubMed ID: 25731858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm trial.
    Zeller T; Peeters P; Bosiers M; Lammer J; Brechtel K; Scheinert D; Rastan A; Noory E; Beschorner U
    J Endovasc Ther; 2014 Dec; 21(6):765-74. PubMed ID: 25453876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twelve-month results of the EverFlex stent in the superficial femoral artery.
    Diehl SJ; Gerblich F; Jochum S; Huck K; Keese M; Schoenberg SO; Sadick M
    J Vasc Interv Radiol; 2012 Oct; 23(10):1317-22. PubMed ID: 22840683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First clinical experience with the Innova versus the Protege EverFlex self-expanding bare metal stents in superficial femoral artery occlusions.
    Gabrielli R; Rosati MS; Chiappa R; Millarelli M; Marcuccio L; Siani A; Caselli G
    Thorac Cardiovasc Surg; 2015 Mar; 63(2):158-63. PubMed ID: 25602844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioabsorbable stent implantation vs. common femoral artery endarterectomy: early results of a randomized trial.
    Linni K; Ugurluoglu A; Hitzl W; Aspalter M; Hölzenbein T
    J Endovasc Ther; 2014 Aug; 21(4):493-502. PubMed ID: 25101576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Nitinol Stent for Lesions up to 24 cm in the Superficial Femoral and Proximal Popliteal Arteries: 24-Month Results From the TIGRIS Randomized Trial.
    Laird JR; Zeller T; Loewe C; Chamberlin J; Begg R; Schneider PA; Nanjundappa A; Bunch F; Schultz S; Harlin S; Lansky A; Jaff MR
    J Endovasc Ther; 2018 Feb; 25(1):68-78. PubMed ID: 29285955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shared and differential factors influencing restenosis following endovascular therapy between TASC (Trans-Atlantic Inter-Society Consensus) II class A to C and D lesions in the femoropopliteal artery.
    Iida O; Takahara M; Soga Y; Suzuki K; Hirano K; Kawasaki D; Shintani Y; Suematsu N; Yamaoka T; Nanto S; Uematsu M
    JACC Cardiovasc Interv; 2014 Jul; 7(7):792-8. PubMed ID: 25060024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of surgical bypass with angioplasty and stenting of superficial femoral artery disease.
    Malas MB; Enwerem N; Qazi U; Brown B; Schneider EB; Reifsnyder T; Freischlag JA; Perler BA
    J Vasc Surg; 2014 Jan; 59(1):129-35. PubMed ID: 23891488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mid-term outcome after endovascular therapy in the superficial femoral and popliteal artery using long stents.
    Schoenefeld E; Donas KP; Schönefeld T; Osada N; Austermann M; Torsello G
    Vasa; 2012 Jan; 41(1):49-56. PubMed ID: 22247060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penetration rate of the placement of a drug-eluting stent for the treatment of superficial femoral artery lesions in Japan.
    Mori S; Hirano K; Yamauchi Y; Hayashi E; Doijiri T; Takamura T; Maeda A; Okuda J; Mizuno K; Onishi Y; Iwaki T; Tsukahara K; Shinozaki N; Araki H; Kongoji K; Sugano T; Miyamoto A; Michishita I
    Heart Vessels; 2017 Sep; 32(9):1093-1098. PubMed ID: 28451834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deployment of self-expandable stents for complex proximal superficial femoral artery lesions involving the femoral bifurcation with or without jailed deep femoral artery.
    Yamawaki M; Hirano K; Nakano M; Sakamoto Y; Takimura H; Araki M; Ishimori H; Ito Y; Tsukahara R; Muramatsu T
    Catheter Cardiovasc Interv; 2013 May; 81(6):1031-41. PubMed ID: 22639451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of demographic factors and lesion severity on iliac stent patency.
    Roach AN; Larion S; Ahanchi SS; Ammar CP; Brandt CT; Dexter DJ; Panneton JM
    J Vasc Surg; 2015 Sep; 62(3):645-53. PubMed ID: 26094046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of polytetrafluoroethylene-covered stent versus bare-metal stent in the primary treatment of severe iliac artery obstructive lesions.
    Piazza M; Squizzato F; Spolverato G; Milan L; Bonvini S; Menegolo M; Grego F; Antonello M
    J Vasc Surg; 2015 Nov; 62(5):1210-8.e1. PubMed ID: 26254822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term clinical and quality of life outcomes after stenting of femoropopliteal artery stenosis: 3-year results from the STROLL study.
    Bunte MC; Cohen DJ; Jaff MR; Gray WA; Magnuson EA; Li H; Feiring A; Cioppi M; Hibbard R; Gray B; Khatib Y; Jessup D; Patarca R; Du J; Stoll HP; Massaro J; Safley DM;
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):106-114. PubMed ID: 29521013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.